A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model

Journal of Zhejiang University: Science B

Volumn 9, Issue 8, 2008, Pages 602-609

  Huang, Feng Ying ^a   Li, Yue Nan ^a   Wang, Hua ^a   Huang, Yong Hao ^a   Lin, Ying Ying ^a   Tan, Guang Hong ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

Recombinant fusion protein; Thrombogenesis; Tissue factor (TF); Vascular endothelial growth factor (VEGF)

Indexed keywords

COMPLEMENTARY DNA; HYBRID PROTEIN; RECOMBINANT THROMBOPLASTIN; RECOMBINANT THROMBOPLASTIN VASCULOTROPIN; RECOMBINANT VASCULOTROPIN; THROMBOPLASTIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOGENESIS; TISSUE SPECIFICITY; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CLONING, MOLECULAR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PLASMIDS; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS; PROKARYOTA;

EID: 48749124661     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B0820120     Document Type: Article

References (28)

1. Boehm, T., Folkman, J., Browder, T., O'Reilly, M.S., 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390(6658):404-407. [doi:10.1038/37126]
2. Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Manseau, E.J., Dvorak, H.F., Senger, D.R., 1993. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143(5):1255-1262.
3. Davie, E.W., Fujikawa, K., Kisiel, W., 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry, 30(43):10363-10370. [doi:10.1021/bi00107a001]
4. Denekamp, J., 1993. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol., 66(783):181-196.
5. Dvorak, H.F., Nagy, J.A., Dvorak, A.M., 1991. Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies. Cancer Cells, 3(3):77-85.
6. Ferrara, N., 2004. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev., 25 (4):581-611. [doi:10.1210/ er.2003-0027]
7. Folkman, J., 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82 (1):4-6. [doi:10.1093/jnci/82.1.4]
8. Folkman, J., 1992. The role of angiogenesis in tumor growth. Semin Cancer Biol., 3 (2):65-71.
9. Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T.F., Pelletier, N., Ferrara, N., 2001. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J. Biol. Chem., 276(5):3222-3230. [doi:10.1074/jbc.M002016200]
10. Hu, P., Yan, J., Sharifi, J., Bai, T., Khawli, L.A., Epstein, A.L., 2003. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res., 63(16):5046-5053.
11. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T.S., Thorpe, P.E., 1997. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275(5299):547-550. [doi:10.1126/science.275.5299.547]
12. Huang, X., Ding, W.Q., Vaught, J.L., Wolf, R.F., Morrissey, J.H., Harrison, R.G., Lind, S.E., 2006. A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood, 107(3):980-986. [doi:10.1182/blood-2005-07-2733]
13. Jain, R.K., 1994. Barriers to drug delivery in solid tumors. Sci. Am., 271(1):58-65.
14. Jiao, J.G., Li, Y.N., Wang, H., Liu, Q., Cao, J.X., Bai, R.Z., Huang, F.Y., 2006. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig. Liver Dis., 38(8):578-587. [doi:10.1016/j.dld.2006.04.014]
15. Kerbel, R.S., 1991. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays, 13(1):31-36. [doi:10.1002/bies.950130106]
16. Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M., Seon, B.K., 1999. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res., 5(2):371-382.
17. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N.P., Risau, W., Ullrich, A., 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72 (6):835-846. [doi:10.1016/ 0092-8674(93)90573-9]
18. Paleolog, E.M., 1996. Angiogenesis: A critical process in the pathogenesis of RA-a role for VEGF? Rheumatology, 35(10):917-919. [doi:10.1093/rheumatology/35.10.917]
19. Risau, W., 1997. Mechanisms of angiogenesis. Nature, 386(6626):671-674. [doi:10.1038/386671a0]
20. Robinson, C.J., Stringer, S.E., 2001. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci., 114(5):853-865.
21. Ruf, W., Rehemtulla, A., Morrissey, J.H., Edgington, T.S., 1991. Phospholipid-independent and-dependent interactions required for tissue factor receptor and cofactor function. J. Biol. Chem., 266(4):2158-2166.
22. Shinkai, A., Ito, M., Anazawa, H., Yamaguchi, S., Shitara, K., Shibuya, M., 1998. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J. Biol. Chem., 273(47):31283-31288. [doi:10.1074/jbc.273.47.31283]
23. Tan, G.H., Wei, Y.Q., Tian, L., Zhao, X., Yang, L., Li, J., He, Q.M., Wu, Y., Wen, Y.J., Yi, T., et al., 2004. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur. J. Immunol., 34(7):2012-2021. [doi:10.1002/eji.200424933]
24. Tao, S.F., Chen, L., Zheng, Y.X., Xu, Y., Chen, J., Yu, H., 2006. Proliferation of endothelial cell on polytetrafluoroethylene vascular graft materials carried VEGF gene plasmid. J. Zhejiang Univ. Sci. B, 7(6):421-428. [doi:10.1631/jzus.2006.B0421]
25. Thorpe, P.E., Burrows, F.J., 1995. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res. Treat., 36(2):237-251. [doi:10.1007/BF00666044]
26. Vlodavsky, I., Friedmann, Y., 2001. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest., 108(3):341-347. [doi:10.1172/JCI13662]
27. Wickham, T.J., Haskard, D., Segal, D., Kovesdi, I., 1997. Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol. Immunother., 45 (3-4):149-151. [doi:10.1007/s002620050419]
28. Zachary, I., 2001. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol. Cell Physiol., 280(6):C1375-C1386.